{
    "clinical_study": {
        "@rank": "114383", 
        "arm_group": {
            "arm_group_label": "Herceptin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous\n      Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The\n      anticipated time on study treatment is until disease progression."
        }, 
        "brief_title": "A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer", 
        "completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "condition": "Urinary Tract Cancer", 
        "condition_browse": {
            "mesh_term": "Urologic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients with >=18 years of age;\n\n          -  metastatic urothelial carcinoma;\n\n          -  measurable metastases or local recurrent disease;\n\n          -  no prior chemotherapy for metastatic disease;\n\n          -  HER2 overexpression (IHC [2+] or [3+]).\n\n        Exclusion Criteria:\n\n          -  concomitant chemotherapy or immunotherapy;\n\n          -  active or uncontrolled infection;\n\n          -  solely CNS metastases;\n\n          -  clinically significant cardiac disease, advanced pulmonary disease or severe\n             dyspnoea;\n\n          -  co-existing malignancies diagnosed within last 5 years, except basal cell cancer or\n             cervical cancer in situ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006667", 
            "org_study_id": "ML17600"
        }, 
        "intervention": [
            {
                "arm_group_label": "Herceptin", 
                "description": "Initial dose of 4 mg/kg intravenously, followed by 2 mg/kg intravenously once weekly, until disease progression", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin", 
                "description": "1200 mg/m2 iv on Days 1, 8 and 15 of each 4-week cycle, 6 cycles", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin", 
                "description": "70 mg/m2 iv on Day 2 of each 4-week cycle, 6 cycles", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Trastuzumab", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aschersleben", 
                        "country": "Germany", 
                        "zip": "06449"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dessau", 
                        "country": "Germany", 
                        "zip": "06846"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fulda", 
                        "country": "Germany", 
                        "zip": "36043"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04277"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "zip": "35043"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Weiden", 
                        "country": "Germany", 
                        "zip": "92637"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Pilot Study Evaluating the Effect of a Combination Regimen of Herceptin, Cisplatin, and Gemcitabine on Time to Disease Progression in Patients With Metastatic Urothelial Cancer", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Bundesministerium f\u00fcr Gesundheit (Federal Ministry of Health)"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Time to progression", 
            "safety_issue": "No", 
            "time_frame": "approximately 4.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical benefit rate: complete remission, partial remission, or stable disease", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 4.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}